Overall Survival of CDK4/6-Inhibitor–Based Treatments in Clinically Relevant Subgroups of Metastatic Breast Cancer: Systematic Review and Meta-Analysis
Francesco Schettini(Target (United States)), Daniele Generali(University of Trieste), Fabiola Giudici(University of Padua), Lajos Pusztai(Yale University), M. De Laurentis(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Pietro De Placido(University of Naples Federico II), Antonio Llombart‐Cussac(MedSIR (Spain)), Ida Paris(Agostino Gemelli University Polyclinic), Massimo Cristofanilli(Cornell University), Grazia Arpino(University of Naples Federico II), PierFranco Conte(University of Padua), Sergio Venturini(University of Turin), Mario Giuliano(Regione Campania), Guy Jérusalem(Centre Hospitalier Universitaire de Liège), Lucia Del Mastro(Ospedale Policlinico San Martino), Sabino De Placido, Dejan Juric(Massachusetts General Hospital), Aleix Prat(Hospital Clínic de Barcelona), Angelo Di Leo(Hospital of Prato), Fabio Puglisi(University of Udine)
Cited by 102
Related Papers
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study
|Journal of Clinical Oncology|2000|2.3k
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
|Breast Cancer Research|2010|2.1k